Raising Capital, Gaining Liquidity - Dealing with Institutions and the Public in 2016

10 Nov 2015 08:30 a.m. - 02:00 p.m.

Tel Aviv Hilton Hotel
Tel-Aviv, Israel
Gali Idan

Download Stephen Thau's Presentation Materials

Download Jaclyn Liu's Presentation Materials

Israeli companies that are not public face many issues – How can we obtain the capital we need to grow? Should we consider a strategic investment or distribution agreement with a larger company? How should we communicate with institutional investors and the public generally? This program will help you answer those questions. While the focus will be on med-tech, biotech, health care and other life science companies, the issues they face are similar to the issues confronting all private Israeli technology companies.

The program will feature the following speakers:

  • Dr. Hadar Ron, Managing Partner, Israel HealthCare Ventures
  • Daniel H. Burch, Chief Executive Officer, MacKenzie Partners, Inc.
  • Paul Schulman, Executive Vice President, MacKenzie Partners, Inc.
  • Gera Strommer, Chairman & CEO, NewPace Ltd, Former CEO, MediGuide, Inc.
  • Maya Liquornik, Partner, Meitar Liquornik Geva Leshem Tal, Law Offices
  • Shiri Shaham, Partner, Yigal Arnon & Co.
  • Nir Dash, Partner, Herzog Fox & Neeman
  • Gene Kleinhendler, Partner, Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.
  • Stephen B. Thau, Partner, Morrison & Foerster
  • Jaclyn Liu, Partner, Morrison & Foerster
  • Bruce Mann, Senior Counsel, Morrison & Foerster

Questions the speakers will focus on include:

  • How to approach venture capitalists and what do they consider in investing in life science companies?
  • Who are the institutional investors, how do you establish relations with them, and how do they decide how to invest or vote?
  • What are the pitfalls of seeking investment from strategic investors?
  • Are the Tel Aviv Stock Exchange, Euronext, AIM or other markets alternatives to a U.S. IPO that should be considered?
  • How should you prepare for a successful NASDAQ of NYSE IPO?
  • Is a sale or joint venture with a public company a viable alternative to an IPO?



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.